NCT04780412

Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Neonatal respiratory morbidities represent a common group of post natal complications including respiratory distress syndrome, transient tachypnea of newborn, and persistent pulmonary hypertension of newborn. It is thought that preoperative vaginal misoprostol administration may decrease the incidence of neonatal respiratory morbidity especially transient tachypnea of newborn. And therefore, it may decrease the incidence of admission to neonatal intensive care units for respiratory causes.

Conditions

• Transient Tachypnea of the Newborn
• Neonatal Respiratory Distress

Interventions

Type	Name	Description
DRUG	Misoprostol	Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
DRUG	Placebo	Vaginal placebo pills given 90-120 minutes before an elective caesarian section.

Timeline

• Start date: 2020-09-01
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2021-03-03
• Last updated: 2021-03-03

Locations

1 site across 1 country: Egypt